Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EYPT Eyepoint Pharmaceuticals	$11.01 +2.4%	$9.81	$3.91 ▼ $13.98	$740.97M	1.73	607,049 shs	813,859 shs
KEQU Kewaunee Scientific	$56.51 +0.0%	$51.38	$30.33 ▼ $71.33	$166.51M	0.7	10,954 shs	6,003 shs
LAB Standard BioTools	$1.31	$1.25	$0.92 ▼ $2.32	$497.57M	1.32	1.36 million shs	2.02 million shs
QSI Quantum-Si	$1.17 +0.9%	$1.73	$0.61 ▼ $5.77	$212.86M	2.87	7.21 million shs	7.85 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EYPT Eyepoint Pharmaceuticals	+4.67%	-1.29%	+3.76%	+95.81%	+28.59%
KEQU Kewaunee Scientific	+2.78%	+3.27%	-4.46%	+52.46%	+22.91%
LAB Standard BioTools	+2.75%	+0.77%	-0.76%	+22.43%	-17.61%
QSI Quantum-Si	-3.33%	-19.44%	-32.95%	-23.68%	+39.74%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EYPT Eyepoint Pharmaceuticals	1.9801 of 5 stars	3.5	2.0	2.3	1.7	0.0
KEQU Kewaunee Scientific	1.3577 of 5 stars	0.0	3.0	2.7	1.7	1.3
LAB Standard BioTools	1.7377 of 5 stars	2.0	3.0	2.0	3.3	0.6
QSI Quantum-Si	2.7235 of 5 stars	3.3	3.0	2.1	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EYPT Eyepoint Pharmaceuticals	3.00	Buy	$25.38	130.47% Upside
KEQU Kewaunee Scientific	0.00	N/A	N/A	N/A
LAB Standard BioTools	2.00	Hold	$1.55	18.32% Upside
QSI Quantum-Si	2.67	Moderate Buy	$3.48	197.01% Upside

Current Analyst Ratings Breakdown

Latest KEQU, EYPT, QSI, and LAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	LAB Standard BioTools	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/13/2025	LAB Standard BioTools	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$1.55
8/7/2025	EYPT Eyepoint Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
8/6/2025	EYPT Eyepoint Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$22.00 ➝ $23.00
7/17/2025	LAB Standard BioTools	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/17/2025	EYPT Eyepoint Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$28.00
5/29/2025	EYPT Eyepoint Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
5/19/2025	QSI Quantum-Si	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.50
5/16/2025	QSI Quantum-Si	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/16/2025	EYPT Eyepoint Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $26.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EYPT Eyepoint Pharmaceuticals	$43.27M	17.54	N/A	N/A	$3.57 per share	3.08
KEQU Kewaunee Scientific	$240.47M	0.69	$7.35 per share	7.69	$23.21 per share	2.43
LAB Standard BioTools	$174.43M	2.85	N/A	N/A	$1.27 per share	1.03
QSI Quantum-Si	$3.06M	70.16	N/A	N/A	$1.20 per share	0.98

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EYPT Eyepoint Pharmaceuticals	-$130.87M	-$2.68	N/A	N/A	N/A	-337.93%	-63.80%	-50.72%	N/A
KEQU Kewaunee Scientific	$11.40M	$3.83	14.75	∞	N/A	4.74%	26.02%	9.87%	9/10/2025 (Estimated)
LAB Standard BioTools	-$138.88M	-$0.35	0.00	N/A	N/A	-69.08%	-19.72%	-14.90%	10/29/2025 (Estimated)
QSI Quantum-Si	-$101.01M	-$0.68	0.00	N/A	N/A	-3,120.14%	-44.57%	-39.45%	N/A

Latest KEQU, EYPT, QSI, and LAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	EYPT Eyepoint Pharmaceuticals	-$0.67	-$0.85	-$0.18	-$0.85	$6.82 million	$5.33 million
8/5/2025	Q2 2025	QSI Quantum-Si	-$0.16	-$0.16	N/A	-$0.16	$1.28 million	$0.59 million
6/25/2025	Q4 2025	KEQU Kewaunee Scientific	N/A	$1.95	N/A	$1.63	N/A	$77.15 million
5/15/2025	Q1 2025	QSI Quantum-Si	-$0.17	-$0.11	+$0.06	-$0.11	$0.96 million	$0.84 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EYPT Eyepoint Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KEQU Kewaunee Scientific	N/A	N/A	N/A	N/A	N/A
LAB Standard BioTools	N/A	N/A	N/A	N/A	N/A
QSI Quantum-Si	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EYPT Eyepoint Pharmaceuticals	N/A	8.00	7.79
KEQU Kewaunee Scientific	0.92	2.20	1.59
LAB Standard BioTools	N/A	6.12	5.37
QSI Quantum-Si	N/A	9.43	9.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EYPT Eyepoint Pharmaceuticals	99.41%
KEQU Kewaunee Scientific	32.69%
LAB Standard BioTools	53.74%
QSI Quantum-Si	39.90%

Insider Ownership

Company	Insider Ownership
EYPT Eyepoint Pharmaceuticals	4.46%
KEQU Kewaunee Scientific	13.30%
LAB Standard BioTools	23.16%
QSI Quantum-Si	30.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EYPT Eyepoint Pharmaceuticals	120	68.93 million	65.85 million	Optionable
KEQU Kewaunee Scientific	1,239	2.95 million	2.56 million	Not Optionable
LAB Standard BioTools	620	379.82 million	291.86 million	Optionable
QSI Quantum-Si	150	183.50 million	128.38 million	Optionable

KEQU, EYPT, QSI, and LAB Headlines

Recent News About These Companies

Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 hours ago | businesswire.com

Quantum-Si Updates Corporate Presentation on Growth

August 11 at 10:14 PM | theglobeandmail.com

What is HC Wainwright's Forecast for Quantum-Si Q3 Earnings?

August 10 at 2:31 AM | americanbankingnews.com

HC Wainwright Has Pessimistic View of Quantum-Si Q3 Earnings

August 9, 2025 | marketbeat.com

Quantum-Si to Participate in the UBS Precision Medicine Frontiers Summit

August 8, 2025 | finance.yahoo.com

Quantum-Si's Q2 Loss In Line With Estimates, Revenues Rise Y/Y

August 7, 2025 | zacks.com

Quantum-Si (NASDAQ:QSI) Releases Earnings Results, Meets Expectations

August 6, 2025 | marketbeat.com

Quantum-Si (QSI) Q2 Revenue Falls 47%

August 5, 2025 | fool.com

Quantum-Si incorporated (QSI) Q2 2025 Earnings Call Transcript

August 5, 2025 | seekingalpha.com

Quantum-Si Incorporated (QSI) Reports Q2 Loss, Lags Revenue Estimates

August 5, 2025 | zacks.com

Quantum-Si Reports Second Quarter 2025 Financial Results

August 5, 2025 | businesswire.com

Earnings To Watch: Quantum-Si Inc (QSI) Reports Q2 2025 Result

August 4, 2025 | finance.yahoo.com

QSI Gears Up to Post Q2 Earnings: What's in Store for the Stock?

August 4, 2025 | zacks.com

Quantum-Si (QSI) Projected to Post Quarterly Earnings on Tuesday

July 30, 2025 | marketbeat.com

ARK Investment Management LLC Has $10.46 Million Stock Holdings in Quantum-Si Incorporated (NASDAQ:QSI)

July 27, 2025 | marketbeat.com

Nikko Asset Management Americas Inc. Has $6.92 Million Position in Quantum-Si Incorporated (NASDAQ:QSI)

July 27, 2025 | marketbeat.com

Quantum-Si (NASDAQ:QSI) Trading Down 2.5% - Here's What Happened

July 26, 2025 | marketbeat.com

Quantum-Si to Participate in the Canaccord Genuity 45th Annual Growth Conference

July 21, 2025 | finance.yahoo.com

Quantum-Si to Report Second Quarter 2025 Financial Results on August 5, 2025

July 14, 2025 | businesswire.com

Quantum-Si Shares Sink After Pricing $50 Mln Registered Direct Offering

July 7, 2025 | marketwatch.com

Tesla, Quantum-Si And Other Big Stocks Moving Lower In Monday's Pre-Market Session

July 7, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

KEQU, EYPT, QSI, and LAB Company Descriptions

Eyepoint Pharmaceuticals NASDAQ:EYPT

$11.01 +0.26 (+2.42%)

Closing price 04:00 PM Eastern

Extended Trading

$11.00 -0.02 (-0.14%)

As of 07:56 PM Eastern

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Kewaunee Scientific NASDAQ:KEQU

$56.51 +0.01 (+0.02%)

Closing price 04:00 PM Eastern

Extended Trading

$56.88 +0.37 (+0.65%)

As of 04:10 PM Eastern

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. The company's laboratory products are used in chemistry, physics, biology, and other general science laboratories in the pharmaceutical, biotechnology, industrial, chemical, commercial, educational, government, and health care markets; and technical products are used in facilities manufacturing computers and light electronics and by users of computer and networking furniture. It sells its products primarily through dealers, its subidiaries, and a national distributor. The company was founded in 1906 and is headquartered in Statesville, North Carolina.

Standard BioTools NASDAQ:LAB

$1.31 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.32 +0.00 (+0.38%)

As of 07:12 PM Eastern

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Quantum-Si NASDAQ:QSI

$1.17 +0.01 (+0.86%)

Closing price 04:00 PM Eastern

Extended Trading

$1.18 +0.01 (+0.43%)

As of 07:59 PM Eastern

Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments. It is used in protein identification, protein variants, antibody characterization, biomarker identification, and post translational modification analysis applications. The company was founded in 2013 is headquartered in Branford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time